Litigation Details for HORIZON THERAPEUTICS, LLC v. PAR PHARMACEUTICAL, INC. (D.N.J. 2017)

« Back to Dashboard

HORIZON THERAPEUTICS, LLC v. PAR PHARMACEUTICAL, INC. (D.N.J. 2017)

Docket		Date Filed	2017-08-08
Court	District Court, D. New Jersey	Date Terminated	2018-09-26
Cause	35:271 Patent Infringement	Assigned To	Kevin McNulty
Jury Demand	None	Referred To	Michael A. Hammer
Parties	PAR PHARMACEUTICAL, INC.
Patents	9,561,197
Attorneys	RAVIN R. PATEL
Firms	Law Office of Jason B. Lattimore, Esq.
Link to Docket	External link to docket

Details for HORIZON THERAPEUTICS, LLC v. PAR PHARMACEUTICAL, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-08-08				External link to document

Litigation summary and analysis for: HORIZON THERAPEUTICS, LLC v. PAR PHARMACEUTICAL, INC. (D.N.J. 2017)

Last updated: July 23, 2026

Horizon Therapeutics v. Par Pharmaceutical (2:17-cv-05901) Litigation Summary and Patent/Regulatory Impact

Horizon Therapeutics LLC sued Par Pharmaceutical Inc. (and related defendants) in 2:17-cv-05901 over the HORIZON product implicated by the case’s Orange Book and patent listings. The litigation is best treated as a generic entry/IP barrier matter driven by Hatch-Waxman patent certifications and an FDA-anchored launch timeline. The docket and settlement pattern determine whether Par’s generic launch was enjoined, designed around remaining claims, or resolved through a settlement that fixes an effective “entry window” for the first Paragraph IV design-around.

What patents were at issue in Horizon Therapeutics v. Par Pharmaceutical, 2:17-cv-05901?

Answer (high confidence on case type, low on patent specificity without docket text): The case is a Hatch-Waxman patent infringement action tied to Par’s Abbreviated New Drug Application (ANDA) and an Orange Book patent list for the reference drug. The asserted patents typically fall into one or more of these buckets:

• Drug substance and/or drug product composition patents
• Method-of-use patents (indication or dosing regimen)
• Formulation patents (excipients, release, salt/polymorph)
• Manufacturing or process patents (if the asserted patent list includes them)

Which patent families typically appear in this type of Horizon vs Par litigation?

Common Horizon patent portfolios in Hatch-Waxman disputes (by category, not asserting the same patents without docket confirmation) include:

• Extended-release or formulation differentiation
• Specific dosing regimens for FDA-approved indications
• Process claims that are used for “skinny label” or design-around strategies

What is the legal hook?

In these cases, the complaint generally alleges that the ANDA product, as described in Par’s ANDA certification(s), infringes one or more listed Orange Book patents under 35 U.S.C. § 271(e)(2).

What is the procedural posture in 2:17-cv-05901: filing, motion practice, and key orders?

Answer: The case proceeds on a defined Hatch-Waxman track:

• Complaint filed after Par submits an ANDA with certifications to Orange Book patents
• Infringement and validity contentions set via pleadings, infringement charts, claim construction, and summary judgment motions
• Court issues Markman claim construction and then addresses dispositive issues including validity and noninfringement
• Parties may pursue settlement, resulting in dismissal or a consent judgment with stipulated entry terms

Common milestones that determine commercial leverage

For business planning, three procedural milestones control risk and timing:

1. Claim construction orders (narrow scope, define design-around boundaries)
2. Preliminary injunction motions (lock-in or exit for an at-risk launch)
3. Summary judgment / trial schedules (whether a settlement is likely and when)

When does Horizon v. Par affect generic entry timelines and exclusivity windows?

Answer: The case affects the practical launch timing by:

• Triggering an automatic statutory stay when required by Hatch-Waxman
• Producing an injunction (if granted) that blocks launch until adjudication or settlement
• Setting a settlement “workaround” date that functions as a de facto entry trigger

How courts translate patent litigation into entry dates

The effective entry timeline usually becomes a function of:

• The remaining unexpired asserted patents at the time of final judgment or dismissal
• The settlement’s agreed-upon “effective launch” date
• FDA application status (approval timing and labeling readiness)

How many Paragraph IV patents were likely challenged in this case?

Answer: Hatch-Waxman complaints in this product category typically assert multiple Orange Book patents (often spanning at least one composition/formulation and one method-of-use or manufacturing patent). The exact count and numbers in 2:17-cv-05901 require the complaint’s asserted-patent list and any amended pleadings. Without that docket text, the number cannot be stated as a fact.

Was there a settlement or consent judgment in 2:17-cv-05901? What were the usual terms?

Answer: Horizon vs Par Hatch-Waxman matters frequently resolve via settlement that includes at least one of:

• A fixed date for generic entry
• A covenant not to sue for specified products/labeling/manufacturing
• A stipulation on dismissal after a trigger event
• A damages framework if FDA approves before the agreed entry date

What settlement terms matter for licensing and investor diligence

For diligence and valuation, the key variables are:

• Earliest permissive entry date
• Scope of “skinny label” carve-outs (if any)
• Design-around conditions tied to dosing strength/formulation
• Future patent carve-outs or ongoing obligations for prosecution/appeals

What did the court decide on infringement and validity in this action?

Answer: The dispositive holdings in Hatch-Waxman actions usually address:

• Whether the ANDA product infringes construed claims
• Whether the asserted claims are invalid (commonly under obviousness, lack of novelty, enablement, or indefiniteness)
• Whether any claims are unenforceable due to inequitable conduct (less common as a dispositive basis unless pled strongly)

Business translation

Even a partial win matters because:

• If the asserted set is reduced to fewer surviving claims, the probability of a design-around increases
• If claim construction narrows scope, the ANDA product’s chemical/formulation and labeling become decisive

Which companies besides Par were named, and does it change manufacturing/IP risk?

Answer: Hatch-Waxman defendants often include:

• ANDA applicant (primary)
• Labeler or distributor
• Manufacturing sites or contract manufacturers (depending on how Par structured the case)
• Corporate affiliates

This impacts risk because manufacturing by a different site can:

• Alter the process profile relevant to manufacturing/process claims
• Affect whether design-around conditions are met

What is the impact on FDA approval, labeling, and potential generic launch scenarios?

Answer: A litigation outcome influences:

• Whether the FDA can approve with a specific labeling configuration (or whether an injunction blocks launch)
• Whether the label must include restrictions tied to a method-of-use dispute
• Whether a launch is “at risk” during the pendency of appeal or before a statutory stay lifts

Typical launch scenarios after resolution

1. Enjoined launch until final resolution
2. At-launch design-around if the court narrows claims
3. Settlement-triggered launch with stipulated entry date
4. Dismissal without prejudice with continued FDA work and future challenges

What is the Orange Book status that ties directly to 2:17-cv-05901?

Answer: The case is tethered to the Orange Book patent list for the reference drug. Orange Book status dictates:

• Which patents were subject to Paragraph IV certifications
• Which patents triggered statutory stay
• Which patents remain relevant after partial dismissals or claim withdrawals

Why Orange Book mapping is central

For business users, the Orange Book map determines:

• Remaining claim coverage risk
• Whether a new ANDA (or amendment) could become noninfringing
• Whether the generic launch is blocked or can proceed with an amended certification strategy

How strong is the patent estate for the Horizon product compared with Par’s expected design-arounds?

Answer: Strength is assessed by:

• How many asserted claims survive at the claim construction stage
• Whether invalidity arguments succeed on dispositive grounds
• Whether the ANDA product falls outside construed claim elements

Practical diligence approach

• Courts that adopt narrower claim construction typically benefit the generic if it drives a clear noninfringement position.
• Courts that uphold broad claim interpretations typically preserve the injunction risk.

How does the 2:17-cv-05901 outcome affect other Par ANDAs or competing generics?

Answer: Hatch-Waxman outcomes often influence:

• Similar reformulations across product strengths
• Labeling strategies tied to method-of-use claims
• Settlement terms offered to other challengers, especially if they share the same FDA reference and similar product profiles

Key takeaways

• The case is a Hatch-Waxman action anchored to Orange Book patents and an ANDA pathway, and it functions as a generic entry timing gate.
• The litigation’s effect on the market is determined by procedural orders (especially claim construction) and whether the parties resolved via settlement with a triggered entry date.
• For decision-making, the critical diligence targets are: asserted patent list in the complaint, claim construction results, final rulings, injunction status, and any settlement-triggered launch date.

FAQs

What court handled Horizon Therapeutics LLC v. Par Pharmaceutical Inc. (2:17-cv-05901)?

The action is filed under case number 2:17-cv-05901 and follows the Hatch-Waxman infringement track in the federal district court handling ANDA litigation.

Is 2:17-cv-05901 an ANDA Paragraph IV case?

Yes. The case posture is consistent with a Hatch-Waxman dispute arising from an ANDA with certifications to Orange Book patents.

Can Par launch “at risk” while appeal is pending in this dispute?

That depends on the court’s injunction status, statutory stay status, and any settlement or consent orders. The controlling facts are any final injunction terms and appellate posture.

Do method-of-use patents affect labeling even if formulation claims are invalidated?

Yes. If method-of-use claims survive, labeling restrictions can remain a gating item for launch.

How do settlement covenants typically limit Par’s market entry?

Settlements generally set a permissive entry date and can include covenants not to sue tied to product scope, labeling, and sometimes manufacturing or formulation design-around constraints.

References

1. United States District Court docket for Horizon Therapeutics, LLC v. Par Pharmaceutical, Inc., No. 2:17-cv-05901.